OnKure Therapeutics’ (OKUR) “Buy” Rating Reiterated at HC Wainwright

OnKure Therapeutics (NASDAQ:OKUR)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $40.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 132.15% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. Oppenheimer initiated coverage on shares of OnKure Therapeutics in a report on Thursday, October 10th. They issued an “outperform” rating and a $35.00 price target on the stock. Lifesci Capital upgraded OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, October 10th.

OnKure Therapeutics Price Performance

NASDAQ:OKUR traded up $0.04 during trading hours on Friday, hitting $17.23. 16,629 shares of the company traded hands, compared to its average volume of 30,553. OnKure Therapeutics has a twelve month low of $9.80 and a twelve month high of $77.60. The stock has a market cap of $57.55 million, a P/E ratio of -1.03 and a beta of 0.21.

OnKure Therapeutics (NASDAQ:OKUR) last released its earnings results on Tuesday, August 13th. The company reported ($1.60) earnings per share for the quarter, beating the consensus estimate of ($1.70) by $0.10. As a group, equities research analysts anticipate that OnKure Therapeutics will post -3.87 EPS for the current year.

About OnKure Therapeutics

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.